{"filing":{"accession_number":"0001178913-26-002988","cik":"0002022416","ticker":"SLXNW","company_name":"Silexion Therapeutics Corp","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"zk2635442.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/zk2635442.htm"},"events":[{"id":8080,"run_id":7094,"accession_number":"0001178913-26-002988","anchor_item_number":"5.03","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.73,"summary":"The Company implemented a 1-for-10 reverse share split effective May 28, 2026, approved by shareholders on May 5, 2026, through an amendment to its Memorandum of Association filed with the Cayman Islands Companies Registry. In connection with this capital restructuring, warrant terms were materially modified, including a reduction in the number of shares issuable per warrant to 1/10th and a ten-fold increase in exercise price to $15,525.00, proportionally adjusting warrant holders' economic rights.","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-05-29","form":"8-K","submitted_at":null,"items":[{"id":2653,"accession_number":"0001178913-26-002988","item_number":"3.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses material modifications to warrant terms in connection with a 1-for-10 reverse share split, including proportional adjustments to the number of shares issuable per warrant (reduced to 1/10th) and a ten-fold increase in exercise price to $15,525.00. While this is a structural adjustment tied to a capital event, it does not fit neatly into the standard taxonomy categories (not a dilutive issuance, not a compensation arrangement, not a shareholder vote result). The modification materially affects warrant holders' economic rights and is disclosed under Item 3.03, warranting classification as a material event outside the more specific categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:09:40.635362+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2654,"accession_number":"0001178913-26-002988","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This disclosure reports the effective implementation of a 1-for-10 reverse share split approved by shareholders on May 5, 2026, effected on May 28, 2026 through an amendment to the Company's Memorandum of Association filed with the Cayman Islands Companies Registry. While reverse splits are material corporate actions affecting share structure and trading, they do not fit neatly into the specific event taxonomy (not an amendment to bylaws per se, not a change in fiscal year, and not a dilutive issuance). The event is material to investors as it affects share count, par value, and trading mechanics, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:09:40.635362+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2655,"accession_number":"0001178913-26-002988","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 8.01 incorporates by reference Items 3.03 (creation of a direct financial obligation or an obligation under an off-balance sheet arrangement) and 5.03 (amendments to articles of incorporation or bylaws, or changes in fiscal year). Without access to the full text of those items, the materiality and specific event type cannot be definitively determined. The incorporation suggests a material event, but the nature remains ambiguous—it could range from a covenant breach (Item 2.04 analog) to a routine bylaw amendment. Classified as other_material pending visibility into the referenced items.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:09:40.635362+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2653,"accession_number":"0001178913-26-002988","item_number":"3.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses material modifications to warrant terms in connection with a 1-for-10 reverse share split, including proportional adjustments to the number of shares issuable per warrant (reduced to 1/10th) and a ten-fold increase in exercise price to $15,525.00. While this is a structural adjustment tied to a capital event, it does not fit neatly into the standard taxonomy categories (not a dilutive issuance, not a compensation arrangement, not a shareholder vote result). The modification materially affects warrant holders' economic rights and is disclosed under Item 3.03, warranting classification as a material event outside the more specific categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:09:40.635362+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-05-29"},{"id":2654,"accession_number":"0001178913-26-002988","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This disclosure reports the effective implementation of a 1-for-10 reverse share split approved by shareholders on May 5, 2026, effected on May 28, 2026 through an amendment to the Company's Memorandum of Association filed with the Cayman Islands Companies Registry. While reverse splits are material corporate actions affecting share structure and trading, they do not fit neatly into the specific event taxonomy (not an amendment to bylaws per se, not a change in fiscal year, and not a dilutive issuance). The event is material to investors as it affects share count, par value, and trading mechanics, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:09:40.635362+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-05-29"},{"id":2655,"accession_number":"0001178913-26-002988","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 8.01 incorporates by reference Items 3.03 (creation of a direct financial obligation or an obligation under an off-balance sheet arrangement) and 5.03 (amendments to articles of incorporation or bylaws, or changes in fiscal year). Without access to the full text of those items, the materiality and specific event type cannot be definitively determined. The incorporation suggests a material event, but the nature remains ambiguous—it could range from a covenant breach (Item 2.04 analog) to a routine bylaw amendment. Classified as other_material pending visibility into the referenced items.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:09:40.635362+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-05-29"}]}